slides · global inventory
Metric
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 79,264
Current window 26,701-26,730
Pages 2,643
Rows per page 30
Component
26,701-26,730 of 79,264
12
The chart shows a significant drop in 2023 compared to previous years, with a -58% annotation.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
13
The chart shows a clear shift from corporate-dominated M&A to increased VC and PE participation over the decade.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
14
The slide uses a process-flow style to link acquirers to targets and their strategic context.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
15
The slide uses a clear visual structure to map acquirers to targets and provides bulleted summaries for each transaction.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
16
The slide uses a hub-and-spoke style layout to connect PE firms to their specific portfolio acquisitions.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
20
The chart shows a significant decline in 2023 compared to previous years.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
21
The slide uses a stacked bar chart to show the composition of M&A deals in Mexico over a decade, accompanied by a table of CAGR metrics and a list of qualitative highlights.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
22
The slide uses a process-flow style to show acquirer-target relationships.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
23
The slide uses a case study format to highlight market activity.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
24
Includes a footer with additional relevant deals and source attribution.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
27
The chart highlights a shift in sector focus for M&A activity in Colombia over a decade.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
28
The chart shows a clear decline in total deal volume over the decade, with a shift in investor composition.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
29
The chart shows a clear peak in deal volume in 2018 followed by a decline, with a specific callout for a 30% drop between 2021 and 2023.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
30
The chart highlights the dominance of the Oil, Gas, Energy, and Mining sector, while TMT's share increases over time. A callout indicates a -24% change between 2021 and 2022.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
03
The chart uses a dual-line plot to show the divergence between healthcare and general inflation, with a shaded region for the Great Recession.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
05
The chart uses a grouped bar structure to compare annual inflation trends across 12 specific healthcare sub-segments.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
06
The slide uses a dual-axis chart combining line graphs for cumulative change and bar charts for 12-month percentage change.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
05
The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
07
The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
09
The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
12
The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
16
The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
18
The slide highlights the 'me-too' drug development problem in China.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
20
The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
24
The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit